Skip to Main Content

Last month, word spread that a drug was finally shown to slow Alzheimer’s disease, and overnight a 73-year-old Swedish professor made $350 million.

The lucky man, Lars Lannfelt, was not particularly famous. He had done pioneering work on the disease, but it was in the 90s and belonged to a sub-field that, after a litany of failures and one disastrous approval, had fallen from grace. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment